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Abstract
 
One striking feature of spontaneous autoimmune diabetes is the prototypic formation of lym-
phoid follicular structures within the pancreas. Lymphotoxin (LT) has been shown to play an
 
important role in the formation of lymphoid follicles in the spleen. To explore the potential role of
LT-mediated microenvironment in the pathogenesis of insulin-dependent diabetes mellitus
(IDDM), an LT
 
 
 
 receptor–immunoglobulin fusion protein (LT
 
 
 
R–Ig) was administered to
nonobese diabetic mice. Early treatment with LT
 
 
 
R–Ig prevented insulitis and IDDM, sug-
gesting that LT plays a critical role in the insulitis development. LT
 
 
 
R–Ig treatment at a late
stage of the disease also dramatically reversed insulitis and prevented diabetes. Moreover,
LT
 
 
 
R–Ig treatment prevented the development of IDDM by diabetogenic T cells in an adop-
tive transfer model. Thus, LT
 
 
 
R–Ig can disassemble the well established lymphoid microenvi-
ronment in the islets, which is required for the development and progression of IDDM.
Key words: adhesion molecule • autoimmune diabetes • insulitis • lymphotoxin • 
lymphotoxin 
 
 
 
 receptor
 
Introduction
 
Insulin-dependent diabetes mellitus (IDDM) is a T cell–
mediated autoimmune disease in which the insulin-secret-
ing 
 
 
 
 cells are selectively destroyed after weeks or months
of insulitis. Much of our current knowledge about the
complex pathogenesis of IDDM derives from the studies of
nonobese diabetic (NOD) mice (1–5). In NOD mice, infil-
tration of autoreactive T cells into the islets is essential for
the development of IDDM. Studies performed in these ani-
mals have revealed that the influx of T cells into the pan-
creas is associated with an increased expression of adhesion
molecules. However, factors that upregulate adhesion mol-
ecules in the pancreas have not been identified. Lymph
node–like structures with de novo formation of lymphoid
follicles are gradually established within the islets over 2–3
mo, with initial cellular infiltration starting at 3–4 wk of age
(1, 3, 4, 6, 7). While the formation of lymphoid follicular
structures is a prototypic feature of chronic progressive in-
flammation (6–8), the molecular mechanisms by which the
lymphoid follicles are formed and the role of these follicles
in the pathogenesis of IDDM have not been well defined.
The interaction between membrane lymphotoxin (LT)
and its receptor is essential for the development and mainte-
 
nance of the lymphoid microenvironment (9–15). LT
 
 
 
 
 
/
 
 
 
mice and wild-type mice treated with LT
 
 
 
 receptor–
immunoglobulin fusion protein (LT
 
 
 
R–Ig) exhibit altered
lymphoid microenvironment. This effect is likely caused by
a failure to induce lymphoid tissue chemokines and adhe-
sion molecules (12–15). These results imply that LT may be
a master cytokine responsible for the formation of lymphoid
structures in chronic inflammation and autoimmune dis-
eases, such as IDDM. Here, we report that administration
of LT
 
 
 
R–Ig reverses the formation of lymphoid follicles,
prevents 
 
 
 
 cell destruction by autoreactive T cells, and
forestalls the development of IDDM.
 
Materials and Methods
 
Reagents and Mice.
 
The generation and production of recom-
binant LT
 
 
 
R–Ig has been described previously (15, 16). The
murine LT
 
 
 
R–human Ig in culture supernatants of BHK/VP16
(15) or Chinese hamster ovary cells (16) was purified on a protein
A column. No difference could be found between the two prep-
arations. Human Ig was obtained from Biogen, Inc. or Sigma-
Aldrich. Female NOD mice were purchased from The Jackson
Laboratory and maintained under specific pathogen–free condi-
tions at the University of Chicago. Antibodies to vascular cell
adhesion molecule (VCAM), peripheral lymph node addressin
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(PNAd; MECA 79), mucosal addressin cell adhesion molecule 1
(MAdCAM-1; MECA367), B220, CD4 (GK1.5), CD8 (3.155),
and CD11c (N418) were purchased from PharMingen.
 
LT
 
 
 
R–Ig Treatment and Measurement of Blood Glucose.
 
NOD
mice were given 100 
 
 
 
g of LT
 
 
 
R–Ig or human Ig intraperito-
neally once per week for 3 wk or as indicated. The glucose con-
centration in blood obtained from a tail vein was measured using
SureStep
 
®
 
 strips (Johnson and Johnson). Diabetes was monitored
by levels of blood glucose. Animals were considered diabetic after
two consecutive measurements of 
 
 
 
250 mg/dl of glucose.
 
Adoptive Transfer.
 
Recipient NOD mice (7–9 wk) were irra-
diated with 6 Gy (199 rads/min) using a 
 
137
 
Cs irradiator. 2 h later,
the mice were injected intravenously with 2 
 
  
 
10
 
7
 
 splenocytes
from diabetic NOD mice in 0.2 ml of PBS, followed by intra-
peritoneal injection with 100 
 
 
 
g of LT
 
 
 
R–Ig, anti–MAdCAM-1,
or control human Ig.
 
Histology and Immunohistochemistry.
 
Pancreatic tissue was col-
lected 10 d after the last LT
 
 
 
R–Ig treatment. Hematoxylin and
eosin staining was performed on 6-
 
 
 
m sections of 10% formalin-
fixed tissue. Infiltration into islets was examined microscopically
and counted by a third party pathologist. Sections were prepared
on multiple levels, and 20–40 randomly chosen islets per mouse
were semiquantitatively classified according to the severity of in-
sulitis: moderate and severe insulitis are defined to be less or more
than half of the structure was infiltrated, respectively. Additionally,
some of the pancreata and spleen were frozen at –70
 
 
 
C in OCT
compound for immunohistology. 6-
 
 
 
m cryostat sections were in-
cubated with rat antibodies to CD3 (L363–29B), VCAM, PNAd
(MECA 79), MAdCAM-1 (MECA367), B220, CD4 (GK1.5),
CD8 (3.155), hamster antibody to CD11c (N418), or species- and
isotype-specific nonreactive control mAbs overnight at 4
 
 
 
C. The
next day, room temperature incubation with biotinylated rabbit
anti–rat or goat anti–hamster secondary antibody (Vector Labora-
tories) for 30 min was followed by a 1-h incubation with strepta-
vidin–horseradish peroxidase complex (Vector Laboratories).
 
Results
 
Prevention of Diabetes by the Administration of LT
 
 
 
R–Ig.
 
Typically, 65–75% of untreated NOD mice in our colony
develop IDDM by 25 wk. To study the role of membrane
LT at an early stage of the disease, 3–4-wk-old NOD female
mice were treated weekly with LT
 
 
 
R–Ig (100 
 
 
 
g/wk) for
3 wk. Only one of the NOD mice treated with LT
 
 
 
R–Ig
developed IDDM by 32 wk, while 67% of the NOD mice
treated with control Ig developed IDDM by 26 wk (Fig. 1
A). To study whether LT
 
 
 
R–Ig treatment reduced IDDM
after the initial phase, female NOD mice were treated with
the soluble receptor at 6–7 wk of age, a time when many is-
lets are infiltrated with autoreactive T cells. Treatment with
LT
 
 
 
R–Ig at this time similarly prevented the development
of IDDM, while the majority of control mice developed the
disease by 25 wk (Fig. 1 B). These results suggest that LT is
essential for the early development of IDDM.
Previous studies have shown that CD4
 
 
 
CD25
 
 
 
 regula-
tory cells control spontaneous autoimmune diabetes, even
at late stages, by limiting the destructive infiltrate in the is-
lets (17). We previously reported that both B7
 
 
 
/
 
 
 
 mice and
CD28
 
 
 
/
 
 
 
 NOD mice exhibited severe insulitis and accel-
erated disease as a consequence of a reduced number of
these suppressor cells (17, 18). To study whether LT was
Figure 1. LT R–Ig treatment prevents diabetes in young NOD mice.
Young NOD mice (n   10) 3–4 (A) and 6–7 wk of age (B), were treated
intraperitoneally with LT R–Ig or control human Ig for 3 wk. (C)
Young CD28 /  NOD mice (n   5 per group) of 3 wk of age were
treated intraperitoneally with LT R–Ig or PBS for 4 wk. Incidence of
diabetes was evaluated at weekly intervals. 
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functioning by altering this regulatory T cell subset,
CD28
 
 
 
/
 
 
 
 NOD mice, deficient in CD4
 
 
 
CD25
 
 
 
 T cells,
were treated weekly with LT
 
 
 
R–Ig or control Ig for 4 wk
starting at 3 wk of age and examined for disease incidence.
All of the control mice developed IDDM by 11 wk of age,
similar to the time course observed in previous experi-
ments. In contrast, there was a delay in disease onset in the
LT
 
 
 
R–Ig-treated mice. In fact, some of the mice were free
of IDDM for an additional 10–13 wk (Fig. 1 C). Similar
retarded diabetes was found in CD28
 
 
 
/
 
 
 
 NOD mice that
were only treated twice with the fusion protein beginning
at the ages of 4 and 5 wk. However, the number of
CD4
 
 
 
CD25
 
 
 
 T cells in the spleens of LT
 
 
 
R–Ig-treated
mice remained comparable with that in the control group
(data not shown). Therefore, these results suggest a critical
role for LT in the development of IDDM in this acceler-
ated model (Fig. 1 C), which is independent of CD28 and
cannot be attributed to the CD4
 
 
 
CD25
 
 
 
 T cell pathway.
 
Reversal of Islet Destruction by Preexisting Diabetic T Cells
Using LT
 
 
 
R–Ig.
 
By 10 wk, most islets in NOD mice
show severe infiltration by autoreactive T cells, accompa-
nied by early signs of islet cell destruction. Very few re-
agents have been shown to block the development of
IDDM at this late stage (5, 19). To determine whether the
effect of LT
 
 
 
R–Ig could prevent the development of
IDDM at this late phase, 10-wk-old NOD mice were sim-
ilarly treated weekly with LT
 
 
 
R–Ig over 3 wk. None
of the LT
 
 
 
R–Ig-treated NOD mice became diabetic,
whereas most of control NOD mice developed IDDM by
25 wk (Fig. 2 A). To study whether LT
 
 
 
R–Ig treatment
just retarded the development of IDDM for a few more
days or had a prolonged protection, we extended our ob-
servation up to 38 wk and found that none of the LT
 
 
 
R–
Ig-treated NOD mice became diabetic. More astonish-
ingly, two doses of LT
 
 
 
R–Ig blocked the development of
diabetes in 85% of prediabetic NOD mice (11/13) treated
as late as 14 wk of age, a time point when some NOD mice
(two mice from each group) were already diabetic, with
nearly all the islets attacked by autoreactive T cells (Fig. 2
B). Only 15% (2/13) of prediabetic mice treated with
LT
 
 
 
R–Ig developed IDDM at 20 wk of age, whereas most
of the control Ig–treated group (63%) developed IDDM by
18 wk of age. These findings suggest that LT also plays an
important role in the late phases of the disease. However,
treatment failed to reverse IDDM in the mice that were al-
ready diabetic at the time of treatment.
The transfer of splenocytes from diabetic NOD mice
into irradiated NOD recipient results in diabetes within a
few weeks, due to acute infiltration of donor autoreactive
T cells into islets. To further address whether the adminis-
tration of LT
 
 
 
R–Ig can prevent diabetogenic T cells from
destroying islet cells, splenocytes from diabetic NOD mice
were transferred into irradiated NOD recipients treated
with a single dose of LT
 
 
 
R–Ig. The development of
IDDM in these irradiated mice was prevented (Fig. 2 C).
These results support a model wherein the use of LT
 
 
 
R–Ig
can prevent the development of IDDM mediated by pre-
existing autoreactive T cells in the circulation.
Figure 2. LT R–Ig treatment blocks autoreactive T cell–mediated is-
let destruction. (A) NOD (10 wk of age) female mice (n   10) were
given weekly intraperitoneal injection of 100  g of LT R–Ig or human
Ig for 3 wk. (B) NOD (14 wk of age) female mice were given weekly
intraperitoneal injection of 100  g of LT R–Ig (n   13) or human Ig
(n   8) for only 2 wk. Blood glucose levels were checked weekly after
the end of treatment (A and B). (C) Sublethally irradiated NOD female
mice (10 mice per group at 7–9 wk of age) were injected intravenously
with 2   107 splenocytes from mice with diabetes and treated with a sin-
gle intraperitoneal injection of 100  g of LT R–Ig or human Ig. Blood
glucose levels were checked weekly starting 1 wk after adoptive transfer. 
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Prevention and Resolution of Insulitis after LT
 
 
 
R–Ig Ther-
apy.
 
One striking feature of IDDM in NOD mice is the
prototypic formation of lymphoid follicular structures
within the pancreas. The profound blockade of different
stages of IDDM by LT
 
 
 
R–Ig treatment may be attributed
to the reduction or even reversal of LT-mediated lym-
phoid structures in the pancreas. To test this, 3–4- or 10-
wk-old NOD mice were treated weekly with LT
 
 R–Ig
and control Ig for 3 wk. 10 d after the end of treatment,
the pancreata were collected for hematoxylin and eosin
staining. As seen in Fig. 3, the number with destructive in-
sulitis and its severity was greatly reduced in both treated
groups of mice during the inductive phase (Fig. 3 A). The
percentage of islets in an early treated group of mice dis-
playing overall infiltration with formation of lymphoid
structures (28.4%) was considerably lower than that ob-
served in the control mice (70.1%; Fig. 3 B). In NOD
mice treated at the late stage (10 wk), only 15% of islets
developed insulitis, and 3% of those showed the formation
of lymphoid structure inside   cells by 14 wk. In contrast,
82% of the corresponding control group demonstrated in-
sulitis and 69% exhibited severe insulitis (Fig. 3 B). The
data also demonstrated that the number and scope of infil-
trating cells in LT R–Ig-treated mice at the age of 14 wk
was reduced far below the level of untreated mice at the
age of 8–9 wk (before the treatment). These results indi-
cate that LT R–Ig treatment not only prevents but also
resolves the formation of lymphoid structures in the pan-
creas. The data also reveal that the infiltration of inflamma-
tory cells and the development of lymphoid follicles may
be a dynamic process and can be reversed once the influx
of cells is blocked.
Figure 3. Reversal of insulitis by LT R–Ig treatment. (a) 4- (A and B)
or 10-wk-old (C and D) NOD mice were treated with control Ig (A and
C) or LT R–Ig (B and D) for 3 wk. The pancreata were collected 10 d
after the end of treatment, and the sections were stained by hematoxylin
and eosin. Representative fields (most common fields) are shown. (b) In-
dividual islets from four mice per group were scored for insulitis at 8 or
14 wk, respectively.1331 Wu et al. Brief Definitive Report
Discussion
Our study demonstrates that the treatment of NOD mice
with LT R–Ig can be effective at blocking both the initia-
tion and effector phases of diabetes. More importantly, such
treatment reverses insulitis and prevents the formation of
lymphoid follicles, even when insulitis is well established
and diabetogenic T cells are clearly present. Such treatment
at either early or late stage has prolonged the protection,
suggesting that short-term treatment with LT R–Ig could
significantly alter the course of IDDM. Several possible
mechanisms may be associated with this treatment. First, as
both LT and LIGHT bind LT R in vitro, these effects may
arise from blockage of LIGHT signaling. LIGHT is a co-
stimulatory molecule through its receptor, herpes virus en-
try mediator, that has been shown to promote T cell prolif-
eration and IFN-  production (20). Its biological activity in
vivo, however, has not been well defined. Further dissec-
tion of the role of LIGHT is difficult due to the lack of re-
agents that effectively block LIGHT activity in vivo. Anti-
LT  antibody has an extremely short half-life of 1 d, while
the half-life of LT R–Ig is 7 d (16). Second, LT may be a
critical cytokine for the development of the CD4 CD25 
T cells that regulate autoimmunity. Although LT R–Ig in-
hibited the development of the disease in the CD4 CD25 
cell–reduced CD28 knockout NOD mice, there was no in-
crease in the number of regulatory T cells in the spleen dur-
ing or after treatment. There was also no increase of
CD4 CD25  cells in wild-type NOD mice after treatment.
Thus, it appears unlikely that the effects of LT R–Ig treat-
ment are mediated through CD4 CD25  T cells.
The most likely mechanism by which LT R–Ig pre-
vents the development of IDDM is through LT-mediated
expression of adhesion molecules and chemokines and the
formation of lymphoid tissues (9–15). Compared with
other adhesion molecules, such as VCAM-1 and PNAd,
the expression of MAdCAM-1 is more closely associated
with the development of insulitis. In fact, treatment of
NOD mice with anti–MAdCAM-1 antibody (MECA367)
alone can reduce insulitis and prevent the development of
IDDM (21). Interestingly, both LT R–Ig and anti-LT 
antibody can very efficiently block the expression of MAd-
CAM-1 in the spleen (12, 13). We found that the expres-
sion of MAdCAM-1 in the pancreas and spleen was readily
reduced after the administration of LT R–Ig. To directly
test whether blocking MAdCAM-1 can prevent the migra-
tion of autoreactive T cells, NOD mice that received T
cells from diabetic mice were treated with anti–MAd-
CAM-1 (MECA367) antibody. Such treatment could pre-
vent or retard the development of IDDM (data not
shown). Together, these data suggest that LT-mediated ad-
hesion molecules, such as MAdCAM-1, are at least partially
responsible for the development of IDDM. It is possible
that the expression of MAdCAM-1 and other adhesion
molecules is required for the formation of insulitis or lym-
phoid follicles in the pancreas. It has been proposed re-
cently that the expression of membrane LT is required for
the formation of large lymphoid follicles in the islets of B
lymphocyte chemokine–mediated transgenic mice (8). We
have previously showed that the migration of dendritic
cells into the spleen is impaired in LT R–Ig-treated mice
(15). It is possible that the chemokines and adhesion mole-
cules reduced by LT R–Ig treatment slow the influx of
inflammatory cells into the pancreas. In this study, we
demonstrated that LT R–Ig reduced the formation of
lymphoid follicles and even reversed severe insulitis in
NOD mice. Taken together, these data suggest that LT-
mediated microenvironment is essential for the develop-
ment of lymphoid structure that is required for the devel-
opment of IDDM.
The generation of a genetic defect of the LT gene in
NOD mice is another potential model that could be used
to address the role of LT in the development of IDDM.
Several disadvantages to this model exist, however. First,
intercrossing of the NOD mice with LT  /  mice to re-
tain a defect in both LT and the MHC loci is an impractical
task, as the locus of LT is very close to that of MHC class
II, which is a key genetic locus for the development of
IDDM. Second, LT  /  mice lack organized lymph
nodes, which may be critical for the development of
IDDM by itself. Such compound defects may complicate
the interpretation of the results. On the other hand, the use
of soluble receptor has several advantages. We can correlate
different phases of the disease with the timing of adminis-
tration of fusion protein. Long-term impact after the termi-
nation of treatment can be readily assessed.
Resolution of severe insulitis by LT R–Ig treatment
suggests that the migration of inflammatory cells into the is-
lets is a dynamic process in which these cells may constantly
move in and out of the target tissue. Interference with this
dynamic process may reduce inflammation, which prevents
further activation of autoreactive T cells and tissue damage.
Interestingly, alteration of the LT-mediated microenviron-
ment by LT R–Ig is a transient effect that ends once the
treatment is terminated. For example, the expression of
splenic MAdCAM-1 and the development of B cell follicles
was gradually restored 4–5 wk after the termination of
LT R–Ig treatment. Thus, the observation that short-term
LT R–Ig treatment has a profound and prolonged impact
on islet destruction may provide a new avenue for the study
of pathogenesis and for the treatment of this disease or
other autoimmune diseases. In the future, it will be inter-
esting to explore whether LT R–Ig treatment may prevent
islet cell rejection by autoreactive or alloreactive T cells.
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